Trends in Use of Midodrine in the ICU: A Single-Center Retrospective Case Series

Mahrukh S. Rizvi, Vrinda Trivedi, Faria Nasim, Erica Lin, Rahul Kashyap, Nicole Andrijasevic, Ognjen Gajic

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

OBJECTIVES: Midodrine is an oral alpha-agonist approved for orthostatic hypotension. The use of midodrine as a vasopressor sparing agent has steadily increased in the ICU despite limited evidence for its safety in that setting. We describe the trends in use and reported side effects and complications of midodrine in multidisciplinary ICUs of a tertiary care institution. DESIGN: Single-center retrospective case series. SETTING: Medical and surgical ICU patients from January 2011 to October 2016 at Mayo Clinic, Rochester. PATIENTS: Adult patients admitted to any ICU who received midodrine for hypotension were eligible.None. MEASUREMENTS AND MAIN RESULTS: We reviewed the mean arterial pressures and cumulative vasopressor dose before and after midodrine administration and assessed for reported complications. During the study period, a total of 1,119 patients were initiated on midodrine, 56% in surgical ICUs, 42% in medical ICUs, and 2% in a mixed medical and surgical neurology ICU. There was a significant decrease in the number of patients on vasopressors 24 hours after initiation of midodrine (663 to 344; p < 0.001); among the patients that remained on vasopressors, there was a significant decrease in the median cumulative vasopressor dose (p = 0.002). There was a significant increase in median mean arterial pressure 24 hours after initiation of midodrine among patients who were not on vasopressors (65-68; p < 0.01). Asymptomatic bradycardia (heart rate < 50 beats/min) was the most common side effect (n = 172 patients, median 39 beats/min). Two patients developed bowel ischemia after initiation of midodrine that prompted discontinuation of midodrine in one case. Evaluating trends of utilization, the off-label use of midodrine has increased steadily over the years across ICUs. CONCLUSIONS: Our results suggest that midodrine is being increasingly used as an adjunct to increase mean arterial pressure and facilitate weaning of vasopressors in the ICU. Prospective trials are required to further establish the appropriate timing, efficacy, safety, and cost-effectiveness of midodrine use in ICU patients.

Original languageEnglish (US)
Pages (from-to)e628-e633
JournalCritical care medicine
Volume46
Issue number7
DOIs
StatePublished - Jul 1 2018

Fingerprint

Midodrine
Arterial Pressure
Off-Label Use
Safety
Orthostatic Hypotension
Vasoconstrictor Agents
Tertiary Healthcare
Bradycardia
Neurology

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Rizvi, M. S., Trivedi, V., Nasim, F., Lin, E., Kashyap, R., Andrijasevic, N., & Gajic, O. (2018). Trends in Use of Midodrine in the ICU: A Single-Center Retrospective Case Series. Critical care medicine, 46(7), e628-e633. https://doi.org/10.1097/CCM.0000000000003121

Trends in Use of Midodrine in the ICU : A Single-Center Retrospective Case Series. / Rizvi, Mahrukh S.; Trivedi, Vrinda; Nasim, Faria; Lin, Erica; Kashyap, Rahul; Andrijasevic, Nicole; Gajic, Ognjen.

In: Critical care medicine, Vol. 46, No. 7, 01.07.2018, p. e628-e633.

Research output: Contribution to journalArticle

Rizvi, MS, Trivedi, V, Nasim, F, Lin, E, Kashyap, R, Andrijasevic, N & Gajic, O 2018, 'Trends in Use of Midodrine in the ICU: A Single-Center Retrospective Case Series', Critical care medicine, vol. 46, no. 7, pp. e628-e633. https://doi.org/10.1097/CCM.0000000000003121
Rizvi MS, Trivedi V, Nasim F, Lin E, Kashyap R, Andrijasevic N et al. Trends in Use of Midodrine in the ICU: A Single-Center Retrospective Case Series. Critical care medicine. 2018 Jul 1;46(7):e628-e633. https://doi.org/10.1097/CCM.0000000000003121
Rizvi, Mahrukh S. ; Trivedi, Vrinda ; Nasim, Faria ; Lin, Erica ; Kashyap, Rahul ; Andrijasevic, Nicole ; Gajic, Ognjen. / Trends in Use of Midodrine in the ICU : A Single-Center Retrospective Case Series. In: Critical care medicine. 2018 ; Vol. 46, No. 7. pp. e628-e633.
@article{ab262a7b4d884c3f8758f9efc28ee28e,
title = "Trends in Use of Midodrine in the ICU: A Single-Center Retrospective Case Series",
abstract = "OBJECTIVES: Midodrine is an oral alpha-agonist approved for orthostatic hypotension. The use of midodrine as a vasopressor sparing agent has steadily increased in the ICU despite limited evidence for its safety in that setting. We describe the trends in use and reported side effects and complications of midodrine in multidisciplinary ICUs of a tertiary care institution. DESIGN: Single-center retrospective case series. SETTING: Medical and surgical ICU patients from January 2011 to October 2016 at Mayo Clinic, Rochester. PATIENTS: Adult patients admitted to any ICU who received midodrine for hypotension were eligible.None. MEASUREMENTS AND MAIN RESULTS: We reviewed the mean arterial pressures and cumulative vasopressor dose before and after midodrine administration and assessed for reported complications. During the study period, a total of 1,119 patients were initiated on midodrine, 56{\%} in surgical ICUs, 42{\%} in medical ICUs, and 2{\%} in a mixed medical and surgical neurology ICU. There was a significant decrease in the number of patients on vasopressors 24 hours after initiation of midodrine (663 to 344; p < 0.001); among the patients that remained on vasopressors, there was a significant decrease in the median cumulative vasopressor dose (p = 0.002). There was a significant increase in median mean arterial pressure 24 hours after initiation of midodrine among patients who were not on vasopressors (65-68; p < 0.01). Asymptomatic bradycardia (heart rate < 50 beats/min) was the most common side effect (n = 172 patients, median 39 beats/min). Two patients developed bowel ischemia after initiation of midodrine that prompted discontinuation of midodrine in one case. Evaluating trends of utilization, the off-label use of midodrine has increased steadily over the years across ICUs. CONCLUSIONS: Our results suggest that midodrine is being increasingly used as an adjunct to increase mean arterial pressure and facilitate weaning of vasopressors in the ICU. Prospective trials are required to further establish the appropriate timing, efficacy, safety, and cost-effectiveness of midodrine use in ICU patients.",
author = "Rizvi, {Mahrukh S.} and Vrinda Trivedi and Faria Nasim and Erica Lin and Rahul Kashyap and Nicole Andrijasevic and Ognjen Gajic",
year = "2018",
month = "7",
day = "1",
doi = "10.1097/CCM.0000000000003121",
language = "English (US)",
volume = "46",
pages = "e628--e633",
journal = "Critical Care Medicine",
issn = "0090-3493",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Trends in Use of Midodrine in the ICU

T2 - A Single-Center Retrospective Case Series

AU - Rizvi, Mahrukh S.

AU - Trivedi, Vrinda

AU - Nasim, Faria

AU - Lin, Erica

AU - Kashyap, Rahul

AU - Andrijasevic, Nicole

AU - Gajic, Ognjen

PY - 2018/7/1

Y1 - 2018/7/1

N2 - OBJECTIVES: Midodrine is an oral alpha-agonist approved for orthostatic hypotension. The use of midodrine as a vasopressor sparing agent has steadily increased in the ICU despite limited evidence for its safety in that setting. We describe the trends in use and reported side effects and complications of midodrine in multidisciplinary ICUs of a tertiary care institution. DESIGN: Single-center retrospective case series. SETTING: Medical and surgical ICU patients from January 2011 to October 2016 at Mayo Clinic, Rochester. PATIENTS: Adult patients admitted to any ICU who received midodrine for hypotension were eligible.None. MEASUREMENTS AND MAIN RESULTS: We reviewed the mean arterial pressures and cumulative vasopressor dose before and after midodrine administration and assessed for reported complications. During the study period, a total of 1,119 patients were initiated on midodrine, 56% in surgical ICUs, 42% in medical ICUs, and 2% in a mixed medical and surgical neurology ICU. There was a significant decrease in the number of patients on vasopressors 24 hours after initiation of midodrine (663 to 344; p < 0.001); among the patients that remained on vasopressors, there was a significant decrease in the median cumulative vasopressor dose (p = 0.002). There was a significant increase in median mean arterial pressure 24 hours after initiation of midodrine among patients who were not on vasopressors (65-68; p < 0.01). Asymptomatic bradycardia (heart rate < 50 beats/min) was the most common side effect (n = 172 patients, median 39 beats/min). Two patients developed bowel ischemia after initiation of midodrine that prompted discontinuation of midodrine in one case. Evaluating trends of utilization, the off-label use of midodrine has increased steadily over the years across ICUs. CONCLUSIONS: Our results suggest that midodrine is being increasingly used as an adjunct to increase mean arterial pressure and facilitate weaning of vasopressors in the ICU. Prospective trials are required to further establish the appropriate timing, efficacy, safety, and cost-effectiveness of midodrine use in ICU patients.

AB - OBJECTIVES: Midodrine is an oral alpha-agonist approved for orthostatic hypotension. The use of midodrine as a vasopressor sparing agent has steadily increased in the ICU despite limited evidence for its safety in that setting. We describe the trends in use and reported side effects and complications of midodrine in multidisciplinary ICUs of a tertiary care institution. DESIGN: Single-center retrospective case series. SETTING: Medical and surgical ICU patients from January 2011 to October 2016 at Mayo Clinic, Rochester. PATIENTS: Adult patients admitted to any ICU who received midodrine for hypotension were eligible.None. MEASUREMENTS AND MAIN RESULTS: We reviewed the mean arterial pressures and cumulative vasopressor dose before and after midodrine administration and assessed for reported complications. During the study period, a total of 1,119 patients were initiated on midodrine, 56% in surgical ICUs, 42% in medical ICUs, and 2% in a mixed medical and surgical neurology ICU. There was a significant decrease in the number of patients on vasopressors 24 hours after initiation of midodrine (663 to 344; p < 0.001); among the patients that remained on vasopressors, there was a significant decrease in the median cumulative vasopressor dose (p = 0.002). There was a significant increase in median mean arterial pressure 24 hours after initiation of midodrine among patients who were not on vasopressors (65-68; p < 0.01). Asymptomatic bradycardia (heart rate < 50 beats/min) was the most common side effect (n = 172 patients, median 39 beats/min). Two patients developed bowel ischemia after initiation of midodrine that prompted discontinuation of midodrine in one case. Evaluating trends of utilization, the off-label use of midodrine has increased steadily over the years across ICUs. CONCLUSIONS: Our results suggest that midodrine is being increasingly used as an adjunct to increase mean arterial pressure and facilitate weaning of vasopressors in the ICU. Prospective trials are required to further establish the appropriate timing, efficacy, safety, and cost-effectiveness of midodrine use in ICU patients.

UR - http://www.scopus.com/inward/record.url?scp=85063707074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063707074&partnerID=8YFLogxK

U2 - 10.1097/CCM.0000000000003121

DO - 10.1097/CCM.0000000000003121

M3 - Article

C2 - 29613861

AN - SCOPUS:85063707074

VL - 46

SP - e628-e633

JO - Critical Care Medicine

JF - Critical Care Medicine

SN - 0090-3493

IS - 7

ER -